- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02285452
Psychophysiological Effects of Thorax Wraps With Ginger and Mustard Flour (SWI_02)
Psychophysiological Efficacy of Thorax Wraps With Ginger or Mustard Flour in Comparison to Wraps With Warm Water in Healthy Subjects - a Randomized, Placebo-controlled, Three-armed Study With Cross-over Design
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Filderstadt, Baden-Württemberg, Germany, 70794
- Filderklinik
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent.
Exclusion Criteria:
Inflectional disease with body temperature > 38 °C. Skin damage on the thorax area Known intolerance or hypersensitivity to mustard or ginger products. Heart failure. Asthma bronchiale. Taking medication with influence on heart rate variability ( mainly tricyclic antidepressants and beta blocker).
Consumption of coffee or nicotine less than three hours before the intervention.
Pregnancy. Deficient knowledge of the German language.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Thorax wrap with ginger flour (Zingiberis Rhizoma plv.)
Thorax wrap with ginger flour, duration max.
20 minutes
|
|
Active Comparator: Thorax wrap with mustard flour (Sinapis nigrea semen)
Thorax wrap with mustard flour, duration max 20 minutes
|
|
Placebo Comparator: Thorax wrap with warm water (placebo)
Thorax wrap with warm water (placebo), duration: 20 minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in temperature
Time Frame: max. 40 minutes
|
Temperature (in °Celsius) of feet, lower legs, hands and face measured with a thermographic infrared camera (pre-post-comparison)
|
max. 40 minutes
|
Respiratory activity (expiratory CO2 and NO-measurement)
Time Frame: max. 40 minutes
|
Physiological parameters are measured for pre-post comparison.
|
max. 40 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Basler Mood Questionnaire (BBS)
Time Frame: 40 minutes
|
filled in by the participants nine times (before and after the thorax wrap and 10 minutes after the intervention)
|
40 minutes
|
Herdecker Wärmeempfindungs-Fragebogen (HeWef)
Time Frame: 40 minutes
|
filled in by the participants nine times (before and after the thorax wrap and 10 minutes after the intervention)
|
40 minutes
|
Warmth perception and skin irritation (NRS)
Time Frame: 40 minutes
|
Warmth perception and skin irritation during the intervention every minute (measured with a numeric rating scale).
|
40 minutes
|
heart rate variability -Parameter (HRV)
Time Frame: Physiological parameters are measured over a period of 40 minutes
|
Standard Deviation of Normal to Normal (heart rate) (SDNN)
|
Physiological parameters are measured over a period of 40 minutes
|
heart rate variability -Parameter (HRV)
Time Frame: Physiological parameters are measured over a period of 40 minutes
|
Root Mean Square of the Successive Differences (RMSSD)
|
Physiological parameters are measured over a period of 40 minutes
|
heart rate variability -Parameter (HRV)
Time Frame: Physiological parameters are measured over a period of 40 minutes
|
ratio low frequency to high frequency (LF/HF)
|
Physiological parameters are measured over a period of 40 minutes
|
heart rate variability -Parameter (HRV)
Time Frame: Physiological parameters are measured over a period of 40 minutes
|
very low frequency (VLF)
|
Physiological parameters are measured over a period of 40 minutes
|
heart rate variability -Parameter (HRV)
Time Frame: Physiological parameters are measured over a period of 40 minutes
|
NN50 (the number of pairs of successive NNs that differ by more than 50 ms)
|
Physiological parameters are measured over a period of 40 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jan Vagedes, Dr., ARCIM-Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SWI_02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States